Edward H. Dixon

Of Counsel

edixon@cov.com
Download V-card

Covington & Burling LLP
1201 Pennsylvania Avenue, NW
Washington, DC 20004-2401
Tel: 202.662.5541


 

Practices

Industries

Education

  • University of Michigan, J.D., 1993
    • cum laude
    • Michigan Law Review, Contributing Editor
  • Columbia University, B.A., 1986
    • magna cum laude
    • Phi Beta Kappa

Bar Admissions

  • Vermont
  • District of Columbia
  • Maryland


Ed Dixon is a member of the firm’s corporate group and is resident in the Washington office.  His practice focuses on the Life Sciences industry.  Mr. Dixon regularly advises pharmaceutical and biotechnology clients on a full range of transactional matters, including complex licensing and collaboration arrangements, acquisitions and divestitures of pharmaceutical companies and products, marketing and co-promotion agreements, and supply and distribution transactions, including authorized generic distribution agreements. 

Representative Matters

  • AstraZeneca in its strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals.
  • Eisai in connection with a marketing and supply agreement with Arena Pharmaceuticals, Inc. for the exclusive right to commercialize lorcaserin for obesity and weight management in North and South America.
  • AstraZeneca in connection with its agreement granting Pfizer worldwide rights to sell an OTC version of AstraZeneca’s blockbuster proton pump inhibitor, Nexium. 
  • AstraZeneca in its global collaboration with The Medicines Company to develop and commercialize acute ischemic heart disease compounds.
  • Eli Lilly and Company in supply and distribution arrangements for its radiopharmaceutical PET imaging agent Amyvid™.
  • Eisai in its worldwide collaboration with Epizyme, Inc. to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.
  • AstraZeneca in a worldwide collaboration with Targacept, Inc. to develop and commercialize a late-stage investigational product for major depressive disorder.
  • AstraZeneca in its co-promotion arrangements with Abbott for AstraZeneca's Crestor® and Abbott’s Trilipix®.

Honors and Rankings

  • Washington DC Super Lawyers (2014) 
  • Legal 500 US, Healthcare: Life Sciences (2013)
  • LMG Life Sciences, "Life Science Star - Finance & Transactional" (2012-2013)

    Print PDF Word Version Print this page